A next-gen platform technology that disrupts the efficacy-toxicity trade-off with clinically validated polymer-drug conjugates for targeted chemotherapy and theranostics.
Superior Therapeutic Index
Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges: The efficacy-toxicity trade-off.
SUPERIOR THERAPEUTIC INDEX
Sagitta® targeted delivery platforms are discovered to improve therapeutic index across a spectrum of payloads, addressing one of oncology’s most persistent challenges:The efficacy-toxicity trade-off.
RS Research announces online abstract acceptance at ASCO Annual Meeting 2025
RS-0139 is RS Research’s lead clinical candidate and is currently being evaluated in Phase I clinical trial. The investigational therapy is designed to deliver docetaxel selectively to integrin receptor-expressing solid tumors.
The abstract reports results from the Phase 1a dose-escalation study, which successfully identified a safe and tolerable dose range for RS-0139. The study represents an important milestone in the clinical development of the Sagitta® platform.
RS Research Co-Founder Prof. Rana Sanyal won the European Prize for Women Innovators
The European Commission announced the winners of the 10th edition of the European Prize for Women Innovators during the opening of Research & Innovation Week in Brussels. In the leading “Women Innovators” category, the award was presented to RS Research Co-Founder Prof. Rana Sanyal in recognition of her outstanding achievements and impact in the field of biotechnology.
RS Research was featured in the cover story of Forbes Türkiye
Recognizing the company as a leading success story in translating scientific research into real-world therapeutic impact, RS Research’s accomplishments in developing targeted therapies were on the cover of Forbes Türkiye September 2025 issue.
